InvestorsObserver
×
News Home

What is Wall Street's Target Price for Forte Biosciences Inc (FBRX) Stock Monday?

Monday, August 15, 2022 01:27 PM | InvestorsObserver Analysts

Mentioned in this article

What is Wall Street's Target Price for Forte Biosciences Inc (FBRX) Stock Monday?

Wall Street is positive on Forte Biosciences Inc (FBRX). On average, analysts give the stock a Buy rating. The average price target is $3.5, which means analysts expect the stock to gain by 171.32% over the next twelve months. That average ranking earns the stock an Analyst Rating of 23, which is better than 23% of stocks based on data compiled by InvestorsObserver.

Overall Score - 3.7
Wall Street analysts are rating FBRX a Buy today. Find out what this means to you and get the rest of the rankings on FBRX!

Why are Analyst Ratings Important?

A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement. InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.

What's Happening With Forte Biosciences Inc Stock Today?

Forte Biosciences Inc (FBRX) stock is lower by -3.01% while the S&P 500 is higher by 0.35% as of 1:26 PM on Monday, Aug 15. FBRX is down -$0.04 from the previous closing price of $1.33 on volume of 305,382 shares. Over the past year the S&P 500 is down -4.12% while FBRX is down -94.58%. FBRX lost -$1.37 per share the over the last 12 months. Click Here to get the full Stock Report for Forte Biosciences Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App